Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
American Heart Journal|February 12, 2021
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD studyWarren H Capell, Elliot S Barnathan, Gregory Piazza, et al.Thrombosis and Haemostasis|January 25, 2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER TrialsJeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 1, 2021
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With BronchiectasisConcetta Lipardi, C Gregory Elliott, Chiara L Sugarmann, et al.Journal of the American Heart Association|February 15, 2021
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical PatientsGary E Raskob, Alex C Spyropoulos, Alexander T Cohen, et al.Journal of the American Heart Association|October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical IllnessGary E Raskob, Walter Ageno, Gregory Albers, et al.Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.Journal of Medicinal Chemistry|August 10, 2021
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class PropertiesPetr Vachal, Joseph L Duffy, Louis-Charles Campeau, et al.Pageof 2